Table 3.
Risk of cancer in biologic-naïve RA patients (including TNFi treated patients prior to TNFi exposure) compared with the general population, with relative risk in the TNFi treated patients compared to biologic naïve patients
| Risk of cancer in biologic-naïve RA patients (including TNFi treated patients prior to TNFi exposure) compared with the general population | TNFi-treated patients compared with no previous exposure to biologics | |||
|---|---|---|---|---|
| Site | O | E | SIR (95 % CI) | RR (95 % CI) b |
| All invasive cancers | 33 | 24.86 | 1.33 (0.94, 1.87) | 0.70 (0.39, 1.25) |
| Melanoma | 5 | 1.97 | 2.54 (1.06, 6.11) | 0.68 (0.16, 2.87) |
| Lung | 6 | 2.55 | 2.35 (1.06, 5.24) | 0.26 (0.05, 1.27) |
| Lymphoid cancersa | 1 | 1.58 | 0.63 (0.09, 4.49) | 4.03 (0.18, 89.28) |
| Colorectal | 2 | 3.6 | 0.56 (0.14, 2.22) | 0.19 (0.003, 13.94) |
| Prostate | 5 | 3.61 | 1.39 (0.58, 3.33) | 1.20 (0.33, 4.40) |
| Female breast | 5 | 3.58 | 1.40 (0.58, 3.36) | 0.20 (0.04, 1.06) |
TNFi tumour necrosis factor inhibitor, RA rheumatoid arthritis, SIR standardised incidence rate, NHL non-Hodgkin’s lymphoma; aLymphoid cancers includes all leukaemias and lymphomas; RR relative risk; b adjusted for age, sex, calendar year, smoking status, methotrexate use and prior malignancy